Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors
STM-01: Phase I EffTox Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy of Solid Tumors
Sponsor: Millennium Pharmaceuticals, Inc.
This PHASE1 trial investigates CNS Malignancy and Genitourinary Neoplasms Malignancy and Gender Unspecified and is currently completed. Millennium Pharmaceuticals, Inc. leads this study, which shows 8 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Jun 2018 — Aug 2019 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
May 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Aug 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Millennium Pharmaceuticals, Inc.
- University of Illinois at Chicago
For direct contact, visit the study record on ClinicalTrials.gov .